The US maternal mortality margin is an anomaly that aggregate health spending cannot explain

The United States spends more on healthcare per person than any other developed country. That much is settled. What is less settled, and less comfortable, is the mounting evidence that the spending is not producing health. Several distinct indicators, drawn from demography, oncology, and public health, now point in the same direction.

Jeremy Grantham, the investor and long-run analyst, frames the maternal mortality picture with striking specificity. The problem, he argues, is not simply that the US performs poorly on this measure among developed nations. It is the size of the margin. As Grantham puts it, “50% more mothers die here than in the second worst country in the developed world.” That is not a narrow underperformance. It is the kind of gap that high aggregate spending cannot easily explain away, and it is the detail that should give pause to anyone inclined to treat US health underperformance as a marginal statistical artifact.

On life expectancy, Grantham points to a gap with Sweden that already stands at six years and, in his view, will widen considerably. He has committed his estate, he says, to a wager: in fifty years, the gap will reach eight or ten years. That is a long time horizon, but the direction of the existing trend lends the prediction more than provocation. A gap that large, sustained and growing, implies something systemic rather than incidental.

50% more mothers die here than in the second worst country in the developed world. Jeremy Grantham

Thomas Seyfried, a cancer researcher, adds a finding worth sitting with on its own terms rather than pressing it into the US-versus-peers frame. High-income countries, including Australia, New Zealand, and the United States, carry the highest cancer rates globally. That grouping places the entire wealthy-nation cohort apart from lower-income nations, not the US apart from its peers. The question it raises is different: something about the conditions of wealthy, industrialized life, whether dietary habits, environmental exposures, or metabolic factors, appears to generate cancer burden that income alone does not offset. For the US, that shared burden lands on top of the maternal mortality and life expectancy gaps Grantham describes, rather than substituting for them.

The institutional picture adds a forward-looking element. Neil deGrasse Tyson reports that the US federal government has shed more than 15,000 scientists within the last two years. That loss does not produce immediate health consequences in the way a hospital closure does. But the federal scientific workforce is the infrastructure through which long-run public health monitoring, disease surveillance, and basic research flow. Erosion at that level tends to show up in outcomes a decade out, not next quarter.

None of these data points is new in isolation. The US has underperformed peer nations on several health metrics for years. What is worth tracking now is the breadth and the simultaneous direction of movement. A maternal mortality outlier at a 50% margin above the next-worst peer, a life expectancy gap that Grantham expects to keep widening, cancer incidence concentrated across the wealthiest nations, and a shrinking federal scientific workforce: these are not obviously unrelated findings. The maternal mortality figure is the sharpest single data point, because the margin removes the ambiguity that usually allows policy arguments to stall on measurement disputes. Whether any single intervention can alter the direction is a separate question. The first step is recognizing what the current indicators actually show.